The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation...
La Jolla Pharmaceutical announced that the Marketing Authorisation Application (MAA) for Giapreza (angiotensin II) Injection for Intravenous Infusion was validated...
The EMA has approved Giapreza (angiotensin II), from La Jolla Pharmaceutical, for the treatment of patients with refractory hypotension in...
La Jolla Pharmaceutical Company announced that it is providing Giapreza (angiotensin II) for an emergency medical program in patients with septic shock due to COVID-19 at the Centre Hospitalier Interrégional Edith Cavell (CHIREC) Delta Hospital in Brussels, Belgium.
GIAPREZA is indicated for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies (see section 5.1).